Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite the absence of strategic updates, the financial performance is strong with a 10% revenue increase, improved gross margins, and a 25% rise in operating income. The positive EPS growth and increased cash flow from operations further support a positive sentiment. The market cap indicates a moderate reaction, leading to a predicted stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Indivior Pharmaceuticals reported a revenue of $200 million for Q1 2026, which represents a 10% increase year-over-year. This growth was driven by strong demand for their flagship product and expansion into new markets.
Gross Margin The gross margin for Q1 2026 was 65%, up from 60% in Q1 2025. The 5% improvement was attributed to cost optimization initiatives and a favorable product mix.
Operating Income Operating income for Q1 2026 stood at $50 million, a 25% increase compared to the same period last year. This was due to higher revenues and improved operational efficiencies.
Net Income Net income for the quarter was $30 million, up 20% year-over-year. The increase was primarily driven by higher operating income and lower interest expenses.
Earnings Per Share (EPS) Earnings per share for Q1 2026 were $0.15, reflecting a 15% increase from Q1 2025. This growth was supported by improved profitability and share repurchase activities.
Research and Development (R&D) Expenses R&D expenses for Q1 2026 were $20 million, a 5% increase year-over-year. The rise was due to increased investment in pipeline development and clinical trials.
Cash Flow from Operations Cash flow from operations was $40 million for Q1 2026, representing a 10% increase compared to the prior year. This improvement was driven by higher net income and better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties, which could result in actual results differing materially from expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brandon Folkes
Chief Commercial
Chief Scientific
Christian Glennie
Commercial Officer
Division Brandon
Division Christian
Division EDT
EDT day
Financial Results
Folkes HC
Glennie Stifel
HC Wainwright
Indivior Pharmaceuticals
Instructions conference
LLC Research
Nadia Indivior
Officer Amsellem
Officer Chief
Pharmaceuticals Financial
President Investor
Relations Nadia
Research Division
Results Conference
Scientific Officer
Stifel Nicolaus
Vice President
Wainwright Co
conference speaker
speaker today
website CEO
INDV Transcript
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Positive4-30
Despite the absence of strategic updates, the financial performance is strong with a 10% revenue increase, improved gross margins, and a 25% rise in operating income. The positive EPS growth and increased cash flow from operations further support a positive sentiment. The market cap indicates a moderate reaction, leading to a predicted stock price increase of 2% to 8% over the next two weeks.
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Positive2-26
Indivior's earnings call highlights strong financial performance, with SUBLOCADE revenue growth and improved cash flow, despite a significant DOJ payment. Optimistic guidance for 2025 and a focus on shareholder returns through share repurchases are positive indicators. While management avoided some specifics, the overall sentiment in the Q&A was positive, with analysts recognizing growth potential in LAI buprenorphine penetration. The company's strategic focus on new therapeutic areas and operational efficiencies further supports a positive outlook. Given the market cap, the stock is likely to see a positive reaction, estimated between 2% to 8%.
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript
Positive10-30
The company has raised its financial guidance for 2025, indicating strong performance and growth expectations. The Q&A section reveals effective cost management and strategic focus on SUBLOCADE's growth, with positive indicators such as increased dispense growth and prescriber base. Despite some management evasiveness, the overall sentiment is positive, supported by strong financial metrics and optimistic guidance.
Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
INDV Slides
INDV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
